The primary endpoint is not IQ but irritability and socialization. Still this shows the benefit of studying genes and intelligence and I predict that the lessons for Arbaclofen will turn out to be more useful than the lessons from the Abecedarian or some other early childhood intervention study.Arbaclofen is different because it was developed by scientists studying the fundamental genetic problems in Fragile X. Arbaclofen is designed to help restore the balance of neurotransmitters, chemical messengers in the brain that communicate between cells."It's not a shot in the dark,"Schultz says. "It's a very rational treatment based on understanding the biology of Fragile X.
Wednesday, September 19, 2012
Fragile X in the news
Seaside therapeutics GABA-B receptor agonist just had a positive phase II trial results: